Our results showed that saroglitazar effectively targeted adiponectin and leptin expression to suppress inflammatory and fibrogenic cytokines such as TNF-α, IL-6, MCP1, and TGF-β in the NASH model. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatohepatitis.